Menstrual toxic shock syndrome (mTSS) is an acute febrile disease accompanied by hypotension and multiple organ involvement. Infection with Staphylococcus aureus producing the superantigen toxic shock syndrome toxin-1 (TSST-1) vaginally is necessary; however, only a small fraction of those infected with TSST-1 producing bacteria actually develop mTSS, suggesting that host factors modulate disease susceptibility. Serum antibodies to the toxin protect against development of the syndrome, but not all antibodies can neutralize the toxin. We set out to determine whether risk of developing the syndrome is related to the absence of neutralizing antibody and if antibody isotypes influence the neutralization capacity. In healthy subjects, TSST-1-binding serum antibodies were exclusively of the IgG and IgM classes; however, toxin-neutralizing capacity was correlated to the TSST-1-specific IgG1 and IgG4 antibodies (r 2=0.88, p<0.0001 and 0.33, p<0.0086, respectively) but not with IgM antibodies. Specific IgA was not detectable. Compared to healthy matched controls who were colonized vaginally with S. aureus, IgG1 anti-TSST-1 antibodies and toxin neutralizing activity was lacking in all of the acute phases and in the majority of convalescent sera, suggesting that these patients may be incapable of generating TSST-1 neutralizing antibodies. These new findings support the hypothesis that host factors are important in the development of mTSS and that the anti-toxin isotype impacts antibody functionality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Schlievert PM: Role of toxic shock syndrome toxin 1 in toxic shock syndrome: Overview. Rev Infect Dis 11(Suppl 11):107–109, 1989
Schlievert PM, Bohach GA, Hovde CJ, Kreiswirth BN, Novick RP: Molecular studies of toxic shock syndrome-associated staphylococcal and streptococcal toxins. In Molecular Biology of Staphylococci, RP Novick (ed). New York, VCH, 1990, pp 313–326
Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD: Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic shock syndrome. J Infect Dis 143:509–516, 1981
Todd J, Fishaut M, Kapral F, Welch T: Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet 2:1116–1118, 1978
Davis JP, Chesney PJ, Wand PJ, LaVenture M: Toxic-shock syndrome: Epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 303:1429–1435, 1980
Osterholm MT, Davis JP, Gibson RW, Mandel JS, Wintermeyer LA, Helms CM, Forfang JC, Rondeau J, Vergeront JM: Tri-state toxic-state syndrome study. I. Epidemiologic findings. J Infect Dis 145:431–440, 1982
Schlech WF III, Shands KN, Reingold AL, Dan BB, Schmid GP, Hargrett NT, Hightower A, Herwaldt LA, Neill MA, Band JD, et al.: Risk factors for development of toxic shock syndrome. Association with a tampon brand. JAMA 248:835–839, 1982
Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, et al.: Toxic-shock syndrome in menstruating women: Association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 303:1436–1442, 1980
Kotb M: Role of superantigens in the pathogenesis of infectious diseases and their sequelae. Curr Opin Infect Dis 5:364–374, 1992
Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, Green K, Peeples J, Wade J, Thomson G, et al.: An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 8:1398–1404, 2002
Norrby-Teglund A, Chatellier S, Low DE, McGeer A, Green K, Kotb M: Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 30:3247–3255, 2000
Basma H, Norrby-Teglund A, Guedez Y, McGeer A, Low DE, El-Ahmedy O, Schwartz B, Kotb M: Risk factors in the pathogenesis of invasive group A streptococcal infections: Role of protective humoral immunity. Infect Immun 67:1871–1877, 1999
Norrby-Teglund A, Ihendyane N, Kansal R, Basma H, Kotb M, Andersson J, Hammarstrom L: Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens. Clin Infect Dis 31:1175–1182, 2000
Kass EH, Parsonnet J: On the pathogenesis of toxic shock syndrome. Rev Infect Dis 9:S482–S489, 1987
Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL, et al.: Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 43:4628–4634, 2005
Reiss MA: Toxic shock syndrome. Prim Care Update Ob Gyns 7:85–90, 2000
Bonventre PF, Linnemann C, Weckbach LS, Staneck JL, Buncher CR, Vigdorth E, Ritz H, Archer D, Smith B: Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis 150:662–666, 1984
Christensson B, Hedstrom SA: Serological response to toxic shock syndrome toxin in Staphylococcus aureus infected patients and healthy controls. Acta Pathol Microbiol Immunol Scand B 93:87–90, 1985
Christensson B, Johansson PJ, Oxelius VA: Imbalanced serum IgG subclass pattern in toxic shock syndrome patients: Deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin 1. Clin Exp Immunol 66:443–449, 1986
Jacobson JA, Kasworm E, Daly JA: Risk of developing toxic shock syndrome associated with toxic shock syndrome toxin 1 following nongenital staphylococcal infection. Rev Infect Dis 11:S8–S13, 1989
Rosten PM, Bartlett KH, Chow AW: Serologic responses to toxic shock syndrome (TSS) toxin-1 in menstrual and nonmenstrual TSS. Clin Invest Med 11:187–192, 1988
Stolz SJ, Davis JP, Vergeront JM, Crass BA, Chesney PJ, Wand PJ, Bergdoll MS: Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis 151:883–889, 1985
Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson JP, Andersson UG, Kotb M: Evidence for the presence of streptococcal superantigen neutralizing antibodies in normal polyspecific IgG (IVIG). Infect Immun 62:5395–5398, 1996
Reingold AL, Hargrett NT, Shands KN, Dan BB, Schmid GP, Strickland BY, Broome CV: Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 96:875–880, 1982
Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP: A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1:1017–1021, 1981
Johnson WM, Tyler SD: PCR detection of genes for enterotoxins, exfoliative toxins, and toxic shock syndrome toxin-1 in Staphylococcus aureus. In Diagnostic Molecular Microbiology: Principles and Applications. Washington, DC, American Society for Microbiology, 1993, pp 294–299
Holtfreter S, Roschack K, Eichler P, Eske K, Holtfreter B, Kohler C, Engelmann S, Hecker M, Greinacher A, Broker BM: Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: A potential explanation for their improved prognosis in severe sepsis. J Infect Dis 193:1275–1278, 2006
Gampfer JM, Samstag A, Waclavicek M, Wolf HM, Eibl MM, Gulle H: Epitope mapping of neutralizing TSST-1 specific antibodies induced by immunization with toxin or toxoids. Vaccine 20:3675–3684, 2002
Cui JC, Hu DL, Lin YC, Qian AD, Nakane A: Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. FEMS Immunol Med Microbiol 45:45–51, 2005
Berkley SF, Hightower AW, Broome CV, Reingold AL: The relationship of tampon characteristics to menstrual toxic shock syndrome. JAMA 258:917–920, 1987
Lanes SF, Rothman KJ: Tampon absorbency, composition and oxygen content and risk of toxic shock syndrome. J Clin Epidemiol 43:1379–1385, 1990
Reingold AL, Broome CV, Gaventa S, Hightower AW: Risk factors for menstrual toxic shock syndrome: Results of a multistate case-control study. Rev Infect Dis 11(Suppl 1):S35–S41 (discussion S41–S32), 1989
Peterson ML, Ault K, Kremer MJ, Klingelhutz AJ, Davis CC, Squier CA, Schlievert PM: The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Infect Immun 73:2164–2174, 2005
Higuchi S, Awata H, Nunoi H, Tsuchiya H, Naoe H, Igarashi H, Matsuda I: A family of selective immunodeficiency with normal immunoglobulins: Possible autosomal dominant inheritance. Eur J Pediatr 153:328–332, 1994
Monteil M, Hobbs J, Citron K: Selective immunodeficiency affecting staphylococcal response. Lancet 2:880–883, 1987
ACKNOWLEDGMENTS
This work was sponsored by the Procter & Gamble Company (P&G). We would like to thank the following individuals for their important technical assistance: Dr. Mark Moore, investigator for West Pharmaceuticals, Inc., and Anita L. Guy of ALG Technical Communications for assistance in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kansal, R., Davis, C., Hansmann, M. et al. Structural and Functional Properties of Antibodies to the Superantigen TSST-1 and Their Relationship to Menstrual Toxic Shock Syndrome. J Clin Immunol 27, 327–338 (2007). https://doi.org/10.1007/s10875-007-9072-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-007-9072-4